SCHEMBL14973649

SCHEMBL14973649

CS(=O)(=O)N1CC2(CCN(C(=O)c3ccc(-c4cccs4)nc3)CC2)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 1.00
NPY5R Q15761 18/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14837517 0.79 HPGDS (1.00) HPGDS
SCHEMBL14974541 0.74 HPGDS (0.62) HPGDS
SCHEMBL740988 0.73 HPGDS (0.58) HPGDSNPY5R
SCHEMBL14986299 0.73 NPY5R (0.67) NPY5R
SCHEMBL6921557 0.72 HPGDS (0.56) HPGDSNPY5R
SCHEMBL652176 0.72 HDAC1 (0.75)
SCHEMBL6216499 0.71 NPY5R (1.00) NPY5R
SCHEMBL761594 0.71 NPY5R (0.56) HPGDSNPY5R
SCHEMBL740490 0.71 HPGDS (0.55) HPGDSNPY5R
SCHEMBL14983918 0.70 NPY5R (0.62) NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2576536-B1 HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS UNIV QUEENSLAND (AU) 2016-09-14 EP disclosed
US-9199976-B2 Haematopoietic-prostaglandin D2 synthase inhibitors THE UNIVERSITY OF QUEENSLAND (AU) 2015-12-01 US disclosed
US-20130137684-A1 HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS THE UNIVERSITY OF QUEENSLAND (AU) 2013-05-30 US disclosed
US-20130137793-A1 Construction Coating Compositions And Methods Of Applying The Same FORMULATED SOLUTIONS LLC (US) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137684-A1 HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS HPGDS, PTGES, PTGIS HPGDS 1/4885NPY5R 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.